Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, has announced its participation in the Bank of America CNS Therapeutics Virtual Conference. The company, which is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, will engage in a fireside chat on Monday, Oct. 7, 2024, at 8:00 a.m. ET.
Interested parties can access the live webcast of the event through the Investors tab on www.acumenpharm.com. The webcast will remain archived on the site for 90 days following the conference, allowing those unable to attend the live session to review the discussion at their convenience.
Positive
- None.
Negative
- None.
News Market Reaction – ABOS
On the day this news was published, ABOS declined 1.21%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Bank of America CNS Therapeutics Virtual Conference on Monday, Oct. 7, 2024, at 8:00 a.m. ET.
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) participating in the Bank of America CNS Therapeutics Virtual Conference?
What is the focus of Acumen Pharmaceuticals' (ABOS) drug development?
How can investors access Acumen Pharmaceuticals' (ABOS) fireside chat at the conference?
What type of company is Acumen Pharmaceuticals (ABOS)?
